• About
  • Contact
  • Resources
  • Book Nook
Donate
  • Featured
  • Commentary
  • Science & News
  • Mainstream
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Michael Lerner’s Blog
    • Guest Authors
MenuClose
  • Featured
  • Commentary
  • Science & News
  • Mainstream Solutions
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative Therapies
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Guest Authors
    • Michael Lerner’s Blog
  • About
  • Contact
  • Resources
  • Donate

ASCO post


Protecting the Immunocompromised From COVID-19: Practical Information for Physicians

Protecting the Immunocompromised From COVID-19: Practical Information for Physicians

by Covid Strategies | Apr 6, 2022 | Science & News

By Chase Doyle COVID-19 may have caught the world off guard in 2020, but in the 2 years since the pandemic began, several effective monoclonal antibodies and antiviral drugs have emerged to protect the most vulnerable patients. The ASCO Post spoke with Gunjan L. Shah,...

read more
Study Finds Black Patients With Cancer Diagnosed With COVID-19 Have Worse Outcomes Than White Patients

Study Finds Black Patients With Cancer Diagnosed With COVID-19 Have Worse Outcomes Than White Patients

by Covid Strategies | Mar 30, 2022 | Science & News

Black patients with cancer experienced significantly worse outcomes after a COVID-19 diagnosis than non-Hispanic White patients, according to findings published by Fu et al in JAMA Network Open. Investigators from the COVID-19 and Cancer...

read more
Risk of COVID-19 Infection and Complications Among Survivors of Childhood, Adolescent, and Young Adult Cancers

Risk of COVID-19 Infection and Complications Among Survivors of Childhood, Adolescent, and Young Adult Cancers

by Covid Strategies | Mar 9, 2022 | Science & News

By Matthew Stenger In a Canadian population-based study reported in the Journal of Clinical Oncology, Gupta et al found that survivors of childhood, adolescent, and young adult cancers were not at a greater risk of COVID-19 infection or severe complications of...

read more
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

by Covid Strategies | Mar 8, 2022 | Featured, Vaccines

By Ajay K. Nooka, MD, et al. ABSTRACT PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit...

read more
T-Cell Responses May Help Predict Protection Against SARS–CoV-2 Infection in Individuals With and Without Cancer

T-Cell Responses May Help Predict Protection Against SARS–CoV-2 Infection in Individuals With and Without Cancer

by Covid Strategies | Feb 23, 2022 | Science & News

T-cell responses directed against the receptor-binding domain of the SARS–CoV-2 spike protein were associated with protection from SARS–CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood...

read more
Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic

Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic

by Covid Strategies | Feb 11, 2022 | Science & News

Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National...

read more
Adverse Event Rates After Two Doses of mRNA COVID-19 Vaccine in Patients With vs Without Cancer

Adverse Event Rates After Two Doses of mRNA COVID-19 Vaccine in Patients With vs Without Cancer

by Covid Strategies | Feb 9, 2022 | Science & News, Vaccines

New research published by Shulman et al in JNCCN—Journal of the National Comprehensive Cancer Network confirmed that mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from a single institution...

read more
TERAVOLT Study Identifies Seven Factors That Increase Mortality Risk for Patients With Lung Cancer Infected With COVID-19

TERAVOLT Study Identifies Seven Factors That Increase Mortality Risk for Patients With Lung Cancer Infected With COVID-19

by Covid Strategies | Feb 2, 2022 | Science & News

The risk of death for patients with SARS–CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published by Alessio Cortellini, MD, in the Journal of Thoracic Oncology. Alessio Cortellini, MD TERAVOLT Data The...

read more
Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment

Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment

by Covid Strategies | Jan 10, 2022 | Mainstream Prevention, Mainstream Solutions, Vaccines

By Matthew Stenger In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving...

read more
Fully Vaccinated Patients With Multiple Myeloma: Rates of SARS–CoV-2 Breakthrough Infection and Hospitalization

Fully Vaccinated Patients With Multiple Myeloma: Rates of SARS–CoV-2 Breakthrough Infection and Hospitalization

by Covid Strategies | Dec 6, 2021 | Mainstream Prevention, Mainstream Solutions, Vaccines

By Matthew Stenger In a U.S. cohort study reported in JAMA Network Open, Wang et al found that fully vaccinated patients with multiple myeloma were at increased risk of breakthrough SARS–CoV-2 infection, and that those with breakthrough infection were more likely...

read more
Response to Third Dose of SARS–CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Response to Third Dose of SARS–CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

by Covid Strategies | Dec 6, 2021 | Mainstream Prevention, Mainstream Solutions, Vaccines

By Matthew Stenger In a single-institution Israeli study reported in a research letter in JAMA Oncology, Rottenberg et al found that a booster dose of the SARS–CoV-2 BNT162b2 mRNA resulted in increased spike protein antibody titers in patients with solid tumors...

read more
COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response

COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response

by Covid Strategies | Dec 6, 2021 | Vaccines

By Caroline Helwick Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common...

read more
Study Finds the COVID-19 Pandemic Created Significant Disruptions in Cancer Screenings at Federally Qualified Health Centers

Study Finds the COVID-19 Pandemic Created Significant Disruptions in Cancer Screenings at Federally Qualified Health Centers

by Covid Strategies | Jul 22, 2021 | Science & News

A new study has found that the COVID-19 pandemic contributed to significant disruptions in breast, colorectal, and cervical cancer screenings at federally qualified health systems spanning 15 states across the United States. The postponed screenings have created...

read more
Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination

Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination

by Covid Strategies | Jul 15, 2021 | Integrative Therapies, Mainstream Prevention, Vaccines

In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection...

read more
All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer

All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer

by Covid Strategies | Jun 18, 2021 | Science & News

6/18/2021 ~ The ASCO Post ~ By Matthew Stenger All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer In a large cohort study reported by Sharafeldin et al in the Journal of Clinical Oncology, researchers from the National COVID Cohort...

read more
Page 1 of 212»

Address:

Commonweal P.O Box 316 | Bolinas, CA 94924

Latest Covid news in your inbox!

Success!

Subscribe

Search Articles

©2021 CovidStrategies/Commonweal | Site maintained by Mercury Multimedia

Privacy Policy | Home